Semaglutide

The most widely studied GLP-1 compound, and the benchmark newer weight-loss peptides are measured against.

Semaglutide is a long-acting copy of GLP-1, the gut hormone released after a meal that tells the brain you have eaten and helps the body handle glucose. It is studied for appetite, weight, blood-sugar regulation, and cardiovascular outcomes, and is an FDA-approved medication in its clinical formulations. A single weekly dose is possible because it binds to albumin in the blood, which stretches its half-life to about a week.

GLP-1 Receptor AgonistWeight & MetabolicGlucose RegulationOnce-Weekly

Why BLP features Semaglutide

Included because it has the deepest human evidence base of any weight-loss peptide: multiple large Phase 3 programs, a cardiovascular outcomes trial, FDA approval, and years of broad clinical use. It is the reference point the newer dual- and triple-target compounds are compared against.

Mechanism

Activates GLP-1 receptors in the brain to reduce appetite and food cravings, so less food feels like enough.

Slows how fast the stomach empties, so fullness lasts longer after a meal.

Boosts glucose-dependent insulin release and lowers glucagon, improving post-meal blood-sugar handling.

A fatty-acid side chain binds albumin in the blood, giving a roughly one-week half-life and once-weekly dosing.

WHAT THE RESEARCH MEASURED

Research findings

Findings describe study outcomes, not expected personal results.

Human research findings

The pivotal STEP 1 trial reported average weight loss of 14.9% at 68 weeks at the 2.4mg weekly dose, versus 2.4% for placebo.
The SELECT cardiovascular outcomes trial reported a 20% reduction in major cardiovascular events in adults with overweight or obesity and existing heart disease, without diabetes.
The SUSTAIN trial program reported substantial HbA1c and fasting-glucose reductions in type 2 diabetes.
Newer compounds report larger effects: Tirzepatide outperformed Semaglutide (20.2% vs 13.7%) in the SURMOUNT-5 head-to-head trial, and combined with Cagrilintide (CagriSema) it reached 22.7% versus 16.1% for Semaglutide alone in REDEFINE-1.
GI side effects (nausea, constipation, diarrhea) were most common during dose escalation and usually eased over time.

Mechanistic & supporting research

GLP-1 receptor pharmacology is among the best-mapped mechanisms in metabolic research.
Albumin-binding half-life extension characterized in pharmacokinetic studies.

Regulatory status

Semaglutide is FDA-approved in its clinical formulations. Material offered here is sold and offered strictly for laboratory and research use and is not a medicine.

Thyroid C-cell tumor warning

Semaglutide’s clinical formulations carry an FDA boxed warning for thyroid C-cell tumors, based on rodent studies; whether this applies to humans is unknown. The labels say not to use them with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Related research

Tirzepatide Cagrilintide Retatrutide Evidence Framework Research Library